Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Olsson

Showing results (591-600 of 632) with videos related to

Pageof 64
Sort By:
Journal of the American College of Cardiology|January 20, 2010
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trialMatti J Tikkanen, Michael Szarek, Rana Fayyad, et al.
Circulation|May 15, 1996
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival StudyT R Pedersen, J Kjekshus, K Berg, et al.
The American Journal of Cardiology|March 26, 1998
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarctionG G Schwartz, M F Oliver, M D Ezekowitz, et al.
JAMA|November 17, 2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialTerje R Pedersen, Ole Faergeman, John J P Kastelein, et al.
Lancet (London, England)|May 6, 1978
Risk factors for ischaemic heart-disease in normal men aged 40. Edinburgh-Stockholm StudyR L Logan, R A Riemersma, M Thomson, et al.
Cancer Research|March 26, 2002
Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestationGaetano Zafarana, Ad J M Gillis, Ruud J H L M van Gurp, et al.
Transplantation|January 25, 2005
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trialBengt Fellström, Hallvard Holdaas, Alan G Jardine, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 1, 2005
Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) StudyAlan G Jardine, Bengt Fellström, John O Logan, et al.
Journal of Medicinal Chemistry|December 18, 2019
<i>In Vivo Veritas</i>: <sup>18</sup>F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 InhibitorsKlas Bratteby, Edvard Torkelsson, Elina Tampio L'Estrade, et al.
Annals of Internal Medicine|February 15, 2001
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic diseaseG Merli, T E Spiro, C G Olsson, et al.
Pageof 64

Showing results (591-600 of 632) with videos related to

Sort By:
Pageof 64
Journal of the American College of Cardiology|January 20, 2010
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trialMatti J Tikkanen, Michael Szarek, Rana Fayyad, et al.
Circulation|May 15, 1996
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival StudyT R Pedersen, J Kjekshus, K Berg, et al.
The American Journal of Cardiology|March 26, 1998
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarctionG G Schwartz, M F Oliver, M D Ezekowitz, et al.
JAMA|November 17, 2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialTerje R Pedersen, Ole Faergeman, John J P Kastelein, et al.
Lancet (London, England)|May 6, 1978
Risk factors for ischaemic heart-disease in normal men aged 40. Edinburgh-Stockholm StudyR L Logan, R A Riemersma, M Thomson, et al.
Cancer Research|March 26, 2002
Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestationGaetano Zafarana, Ad J M Gillis, Ruud J H L M van Gurp, et al.
Transplantation|January 25, 2005
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trialBengt Fellström, Hallvard Holdaas, Alan G Jardine, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 1, 2005
Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) StudyAlan G Jardine, Bengt Fellström, John O Logan, et al.
Journal of Medicinal Chemistry|December 18, 2019
<i>In Vivo Veritas</i>: <sup>18</sup>F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 InhibitorsKlas Bratteby, Edvard Torkelsson, Elina Tampio L'Estrade, et al.
Annals of Internal Medicine|February 15, 2001
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic diseaseG Merli, T E Spiro, C G Olsson, et al.
Pageof 64